{"name":"Kashiv BioSciences, LLC","slug":"kashiv-biosciences-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"FYLNETRA Phase 3 readout (Primary Mediastinal Large B-Cell Lymphoma)","drug":"FYLNETRA","drugSlug":"pegfilgrastim-pbbk","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-12-31","label":"RELEUKO Phase 3 readout (Primary Mediastinal Large B-Cell Lymphoma)","drug":"RELEUKO","drugSlug":"filgrastim-ayow","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-30","label":"FYLNETRA Phase 2 readout (Renal Pelvis and Ureter Urothelial Carcinoma)","drug":"FYLNETRA","drugSlug":"pegfilgrastim-pbbk","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-09-30","label":"RELEUKO Phase 3 readout (Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia)","drug":"RELEUKO","drugSlug":"filgrastim-ayow","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-30","label":"RELEUKO Phase 3 readout (Anaplastic Medulloblastoma, Medulloblastoma)","drug":"RELEUKO","drugSlug":"filgrastim-ayow","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ADL-018 Injection","genericName":"ADL-018 Injection","slug":"adl-018-injection","indication":"Other","status":"phase_1"},{"name":"Fylntera","genericName":"Fylntera","slug":"fylntera","indication":"Other","status":"phase_1"},{"name":"RELEUKO","genericName":"FILGRASTIM-AYOW","slug":"filgrastim-ayow","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"FYLNETRA","genericName":"PEGFILGRASTIM-PBBK","slug":"pegfilgrastim-pbbk","indication":"Decrease incidence of infection in cancer patients","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Xolair Prefilled Syringe","genericName":"Xolair Prefilled Syringe","slug":"xolair-prefilled-syringe","indication":"Moderate to severe allergic asthma","status":"phase_3"}]}],"pipeline":[{"name":"ADL-018 Injection","genericName":"ADL-018 Injection","slug":"adl-018-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FYLNETRA","genericName":"PEGFILGRASTIM-PBBK","slug":"pegfilgrastim-pbbk","phase":"marketed","mechanism":"Pegfilgrastim binds to specific cell surface receptors on hematopoietic cells, stimulating their proliferation, differentiation, and functional activation.","indications":["Decrease incidence of infection in cancer patients","Increase survival in radiation exposure"],"catalyst":""},{"name":"Fylntera","genericName":"Fylntera","slug":"fylntera","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RELEUKO","genericName":"FILGRASTIM-AYOW","slug":"filgrastim-ayow","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Xolair Prefilled Syringe","genericName":"Xolair Prefilled Syringe","slug":"xolair-prefilled-syringe","phase":"phase_3","mechanism":"Xolair (omalizumab) is a monoclonal antibody that binds to circulating immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation.","indications":["Moderate to severe allergic asthma","Chronic idiopathic urticaria","Allergic rhinitis (in some formulations)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQYWt1bHY4WWZQWjRiN0k3cGdnTVpuSVQxbGhuelFpV1RNd3QxM0RTa0FYekN2ZEU5Zm01cVJrUFp5S1ZqQXdxdW0wNUlRQ1FuMDJmZWFuaGl2SVpfSVNtRHdYMWlOR3hpNHJqSUwtVXkwZlRWRTVyNzVlaFJJejJxSGUxbHNsaEVNa25TQ2tEZ3YxdHkwaWRJeg?oc=5","date":"2026-03-27","type":"pipeline","source":"Veloxx media","summary":"Shailesh Limbachiya Named Business Head HR at Kashiv BioSciences LLC - Veloxx media","headline":"Shailesh Limbachiya Named Business Head HR at Kashiv BioSciences LLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQb01fWHhPUGVhY3c4TXpuenNNT0MxOWRnMmMyaTZUdUxqRkVYV1laUUgzVDZRUVBZUWtxTzlFVTNsd2N0VGdzVVV2R1VpbXhCSnVzYWxPRHN4ZEdENmg5bDAxNF9pUHduaTBfdU1KZFNtbEx4bzZKT2ZBSWlLdUJpaU03WUhXclZwMkVXSTRjdElvT2dhZjRpS1JrcEZfYVNEM2VVRjRBSFlnYy1pT1ZiSEduQ25nbGhCOFdWSVZsSTFvTlNDdHVDOUg4ZzIwbEExOFB6MnMzVmllQ1dyaTJxdkZVQ3IwYlFrNlpRanRrWVhDSzYyUWZYZ0ZxUDBGRnVJOFBoVVhGWU1jME9DdUNVTXY3OUM2MVBnQW55XzJoSWVUcENYUWdXdQ?oc=5","date":"2026-02-09","type":"pipeline","source":"Business Wire","summary":"Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India - Business Wire","headline":"Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Produc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPd3h0WW9ZNy0xOGFFRVJyZlJFdmVmckFlNTVfTEVIZVNxTW1oaUNXa0pFRnZiejViaXN5QzFKYXNQUkNOMXZLWTc4UmlSUXZ5WjZuUnh4QWdnWHBaaWoyZmR1QnNsbDVZelRubkhwRnlnNThPYnBCdllUcDBZQk9JUFlEeEcybWN5UHlfVmozVWpSY21zbTNXNjk0OEE1YlJwWTJDOFhTbVlLZ3cyNjZSb0htQjF4dU53YW83QjFQLWxibHcwbnpzQ3RTMXgyYkZ3OFM4aDBTMEcxNWZReURla3FTOGxnQ1NqVHRDVUY4cFJrOWRNeXVEZEtTMDlIbk1tVmRSNi1BMDFMTXZCZW5JNXFn?oc=5","date":"2025-12-22","type":"pipeline","source":"Business Wire","summary":"Kashiv BioSciences Secures INR 648 Crore Financing from Union Bank of India to Expand Manufacturing Facilities in Gujarat, India - Business Wire","headline":"Kashiv BioSciences Secures INR 648 Crore Financing from Union Bank of India to Expand Manufacturing Facilities in Gujara","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-07","type":"regulatory","source":"BioSpace","summary":"Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar ","headline":"Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorizat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNUjB6U1pIT2dRUjIxanFEMXZJRTZCa0FkVzRrWERac0VnT21aU1VTaENSUmRsdWdLbEI1a2oxWTQ4MmVDWUdnX011UmVjTUJmellXMVFDUnl0U0FhNDl6Yy1zbXBKNnQxX2wxeTVZc2YxYzVkLVZyclY2amh2Sk9VRW9Oa0UzMGRreUdVZVhMUEhxRXktQXVxeG5oVlh0SHBhTWJqa25VU2s0czQtRXhIOU45MWh0MXZfNUJxZFVTOWNHX2tRcmFkVHNYVFJ3ak5wTDVkYnlwempZSlg0SUNDQ0J3ZkhERlp3RHBDbVN0aGxrLVYtSzdvbTJB?oc=5","date":"2025-09-24","type":"pipeline","source":"Business Wire","summary":"Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA - Business Wire","headline":"Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOd0l2X3ZteDk1d0ViLTNzcmFUdlBoYTh1WGYtNmlsdk9DSElBcDcxTmdZMWhDOFFCREFRY3BfYXM3Q29rZzhfTHlVVXpxSVBnSnFYSjltZmxiM3p0OHdXd2I0azBOMGcwZjBUa0M2cVB4TFZ0TWhPTDlkNWI1QUF3RlpQNHY4aGcyOGstQlBXcjRpZnB1cnUxM0pVcl9lYlM2Y1V5NE56RWVJQV9ZZUdZUUFDemJUT1pPVWRfQWdtV2lwUGlQQW9tYXdQRmhQRjlyRVdra2JWZTUzNGVnR3Nia1g0WjEwNjZELWl6WTlMcno2ZFJTS3VzY2JnVW9MVDg?oc=5","date":"2025-09-12","type":"patent","source":"businesswireindia.com","summary":"Kashiv BioSciences and CRISTALIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America - businesswireindia.com","headline":"Kashiv BioSciences and CRISTALIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOa3dCS3IxTnlILWFnUVZBMTNmRmZfV2Uxc2dldkpwcE5xRUVTMFlzUE9Xb3NzM0IyclRHa1J1LUFteDJoU3A1azVPX1FLclJnQjBtUE0tLTlVRW93NE5faktOU1BRbWdXN3RfRmhzNURhM0JiQU5vVGdPOWk4RFR4c0pXM1hlSTA?oc=5","date":"2025-08-05","type":"deal","source":"finance.yahoo.com","summary":"Kashiv BioSciences and MS Pharma Enter into MENA License and Supply Agreement for ADL-018, Biosimilar Candidate to XOLAIR® (bOmalizumab) - finance.yahoo.com","headline":"Kashiv BioSciences and MS Pharma Enter into MENA License and Supply Agreement for ADL-018, Biosimilar Candidate to XOLAI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNaGFLMjZReFdjNUN5bFpId3c0akZKbGwwcGtwZDRFTjlZOEFTZzVseGFVeFAtZlZXY2tyMXUwUkRFRTAzU1lHUnI3VlV2M1FENUpiUFhKMS00ZnBFS2FaYm94SVJla0hQUGE2SzJDcGRBOVJjYVBfMmF3cWw1cWhiS0hrRVg0SzI2ci1yTktKaV9PUUpqQTYwQW5XdWZXWC1oaEhhZElDX2x3T1lXOWktOUN6ZnJlYUo3cjZuSTVNb3U1UTJ2OF83TzNRUkJRQ1VreExSTDhDeHkxSW9HZnRJYkNrNGRETlJXc1Q0UzRFdjVhMjBDOHlUOWtIZ3lyNVA2ZG9oS1VLSnphWWM?oc=5","date":"2025-06-25","type":"trial","source":"BioSpace","summary":"Kashiv BioSciences Announces Positive Topline Results from Confirmatory Efficacy Study of ADL-018, Biosimilar Candidate to XOLAIR® (omalizumab) - BioSpace","headline":"Kashiv BioSciences Announces Positive Topline Results from Confirmatory Efficacy Study of ADL-018, Biosimilar Candidate ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOazRDNGxTbGtfVEZHLXpKbmRkUWFTb3NEeVBtdGJOdEx3SDEzLW9UUldvakRmUVVZWno2MkFhaVhYQUtmdU0wWm9PY2VaaF9XQzFpTFY4Zkh6Vnc1OXZ1OUktMmlRbmdVZGhYNzMxdVYtcWNXb0k5amxMUVlnNlV2VW1fWjJaVDROYzAySDl6RDBBUjNiVXY2TVc1U2dFUE1CUE5RYTlGeUR1M0plb3R2aS03YnA0T3BUOVVtX1VTU2dwdGRKS1lDMnExMmdBRmVYSU9tdFhmd21hbEhxVFZJ?oc=5","date":"2025-04-07","type":"pipeline","source":"Business Wire","summary":"Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management - Business Wire","headline":"Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPYjBJYTV3SGMzNkVZeXJfa01yY3BpYmpLYmpjZ09kZW9OeTZpUmR3ajhJallzdHlUeDItZ3Q5NC1rSXdBcWZFYWlTZHVrSkxhQ2ZTdnR2NlFFNG1DRWd2WHFyaXB6REllNlVEQVN1WU5ZTlNqdzZiNlBJaHZSY29HbnE4MXdSZWxjV0c2ZTBGeXhFY3pzQlNXM3lpWjhSdS1waU1yX2Z3RnA0dWFZOUFMaVF1aERtUmNDX1NmUjhHVFliZFNmMHdiTnpLdVFuaWtXTEZQRkJTaDlMNWhwQmxPdDkxRGllb0VoUmlKRjVTUQ?oc=5","date":"2025-02-25","type":"pipeline","source":"Business Wire","summary":"Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada - Business Wire","headline":"Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBjUzZSSV9VaWNTWk1yaUM5enJCNElDTmF6UVo5QjFoa01tUUlJYlM3eFI1b0V4YWxkRXlIdU91S3JmTHBQQjZXbUI4eG9qT08zeEtpNVU4YkttS3VHRksyT2gxVFVmNWJFeFBLSnQxUzhUM0NScG5uNVdFYw?oc=5","date":"2021-01-13","type":"pipeline","source":"NJBIZ","summary":"Amneal Pharma announces acquisition of Kashiv Specialty - NJBIZ","headline":"Amneal Pharma announces acquisition of Kashiv Specialty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQdURwMDFEVDBLZVZ6ZnNsSVc5WkxHU3pteF9ieTFMYUlOSlVxOHNzNjRKcEFva1ZQcTJQYkhlYVlsTXMwTkxZaWJnNVJQdTdEVFMtcW9BcDNQTmt2VUhLcFhweV9EcjhEVktKZEFwbGd2a2JlUlViMFV1b3BoejZKYjR5SEVrZDB0TXV4SEFmU09FYXl5dEc0aUE2SUJpWDFTR1ZNNFN4NGljM0pGQU5ZVV8xNlNXTXVuOC1qWERTNzF0QQ?oc=5","date":"2021-01-13","type":"deal","source":"Pharmaceutical Business review -","summary":"Amneal to acquire substantially all of Kashiv Specialty Pharmaceuticals - Pharmaceutical Business review -","headline":"Amneal to acquire substantially all of Kashiv Specialty Pharmaceuticals - Pharmaceutical Business review -","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":2,"marketed":2,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}